Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

BioFocus Signs Agreement with Biogen Idec

Published: Tuesday, November 12, 2013
Last Updated: Tuesday, November 12, 2013
Bookmark and Share
The 3-year collaboration will focus on the identification and validation of novel targets in scleroderma.

Galapagos’ service division BioFocus will use its SilenceSelect® platform and unique human skin models to deliver new assays and identify validated, novel, disease-modifying targets in scleroderma to Biogen Idec.  Under the terms of the agreement, BioFocus will receive an upfront payment, FTE funding, and will be eligible to receive success payments for target discovery milestones to be delivered by BioFocus and development milestones achieved by Biogen Idec. The total value of this collaboration to BioFocus could reach $31 million.

“We believe Galapagos has unique expertise with relevant human primary cells, positioning them well to find new targets for disease-modifying therapies against scleroderma,” said Jo Viney, vice president of discovery sciences at Biogen Idec.

“We welcome Biogen Idec to our client base and look forward to applying our versatile target discovery engine to yet another new disease area with unmet medical need,” added David Smith, CEO Galapagos Services.

Scleroderma is an autoimmune disease characterized by hardening of the skin.  Patients with diffuse scleroderma also experience hardening of the organs, which can be particularly disabling and also fatal.  Scleroderma is found worldwide, affecting 1 in 1000 in the United States, with women four times more likely than men to develop the disease.  The root causes of the disease are not well understood, and there are no disease-modifying treatments.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

BioFocus Signs Integrated Drug Discovery Collaboration with Boehringer Ingelheim
Under the terms of the agreement, BioFocus will apply its drug discovery services to an undisclosed target within Boehringer Ingelheim’s drug discovery portfolio.
Thursday, November 21, 2013
BioFocus Signs Agreement with Aviva Investors
Pre-let agreement for construction of new laboratory and HQ building at Chesterford Research Park.
Thursday, September 05, 2013
BioFocus Receives Rapid Response Innovation Award from The Michael J. Fox Foundation
Grant will support the development of a novel Parkinson’s disease cell model.
Tuesday, June 25, 2013
BioFocus Launches Academic Engagement Initiative
Aim of the initiative is to identify the best new therapeutic strategy ideas from academic groups.
Wednesday, May 01, 2013
BioFocus Extends its Collaboration with The Michael J. Fox Foundation
BioFocus has extended its collaboration agreement for Parkinson’s Research.
Thursday, April 18, 2013
Peter Rehse joins BioFocus as Senior Director, Structural Biology
BioFocus today announced that Dr. Peter Rehse has joined the company and will be based at Chesterford Park, near Cambridge, UK.
Monday, February 11, 2013
BioFocus Announces Agreement with ChanTest
BioFocus expands ion channel offering.
Thursday, February 07, 2013
BioFocus Achieves Milestone in its Drug Discovery Collaboration with UCB
Discovery milestone triggers payment from UCB and demonstrates BioFocus’ ability to support its clients.
Tuesday, December 04, 2012
BioFocus and Ono Sign a Drug Discovery Agreement
The collaboration agreement between Galapagos NV’s service division, BioFocus, and Ono Pharmaceutical Co., Ltd. will focus on discovering novel drugs in the field of CNS disorders.
Monday, September 03, 2012
BioFocus and Activiomics Announces Strategic Alliance
BioFocus expands its drug discovery offering with proteomics technology from Activiomics.
Thursday, July 26, 2012
BioFocus and Argenta Announce Drug Discovery Collaboration
Collaboration with AstraZeneca in respiratory and inflammatory disease.
Thursday, March 15, 2012
Almirall and BioFocus enter Research Alliance
Three-year integrated drug discovery alliance aims to identify drug development candidates for treating respiratory disease.
Wednesday, January 25, 2012
Argenta and BioFocus Announce Two-Year Extension Of Drug Discovery Collaboration with Genentech
Total potential value of the contract extension is up to £21.5 million (€23.4 million).
Monday, August 22, 2011
BioFocus and InterMed Discovery Announce Marketing Collaboration
The collaboration will offer enhanced natural product discovery to the pharmaceutical, animal health, and agrochemical industries.
Wednesday, August 03, 2011
BioFocus and InterMed Discovery Announce Marketing Collaboration
IMD will make natural product screening libraries available and provide follow-on services to BioFocus.
Wednesday, July 20, 2011
Scientific News
Study Finds Brain Chemicals that Keep Wakefulness in Check
Researchers to develop new drugs that promote better sleep, or control hyperactivity in people with mania.
Sorting Through Cellular Statistics
Aaron Dinner, professor in chemistry, and his graduate student Herman Gudjonson are trying to read the manual of life, DNA, as part of the Dinner group’s research into bioinformatics—the application of statistics to biological research.
Playing 'Tag' with Pollution lets Scientists See Who's It
Using a climate model that can tag sources of soot from different global regions and can track where it lands on the Tibetan Plateau, researchers have determined which areas around the plateau contribute the most soot — and where.
Women’s Immune System Genes Operate Differently from Men’s
A new technology reveals that immune system genes switch on and off differently in women and men, and the source of that variation is not primarily in the DNA.
Long Telomeres Associated with Increased Lung Cancer Risk
Genetic predisposition for long telomeres predicts increased lung adenocarcinoma risk.
First Artificial Ribosome Designed
Researchers at the University of Illinois at Chicago and Northwestern University have engineered a tethered ribosome that works nearly as well as the authentic cellular component, or organelle, that produces all the proteins and enzymes within the cell.
High-Resolution 3D Images Reveal the Muscle Mitochondrial Power Grid
NIH mouse study overturns scientific ideas on energy distribution in muscle.
Expanding the Brain
A team of researchers has identified more than 40 new “imprinted” genes, in which either the maternal or paternal copy of a gene is expressed while the other is silenced.
Identifying a Key Growth Factor in Cell Proliferation
Researchers discover that aspartate is a limiter of cell proliferation.
Study Uncovers Target for Preventing Huntington’s Disease
Scientists from Cardiff University believe that a treatment to prevent or delay the symptoms of Huntington’s disease could now be much closer, following a major breakthrough.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!